eFFECTOR Therapeutics And Dana-Farber Cancer Institute To Collaborate On Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin As Combination Treatment In ER+ Endometrial Cancer And In Low Grade Serous Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
eFFECTOR Therapeutics and Dana-Farber Cancer Institute are collaborating on a Phase 2 clinical trial to evaluate Zotatifin as a combination treatment for ER+ endometrial cancer and low-grade serous ovarian cancer.
May 20, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
eFFECTOR Therapeutics is collaborating with Dana-Farber Cancer Institute on a Phase 2 clinical trial to evaluate Zotatifin for treating ER+ endometrial cancer and low-grade serous ovarian cancer.
The collaboration with a prestigious institution like Dana-Farber Cancer Institute on a Phase 2 clinical trial is a significant milestone for eFFECTOR Therapeutics. Positive outcomes from the trial could lead to further development and potential market approval, boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100